Healthcare -
Biotechnology - NASDAQ - US
$ 0.4315
-5.29 %
$ 34.6 M
Market Cap
1.14
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
CytomX Therapeutics, Inc.
| Current Assets | 107 M |
| Cash & Short-Term Investments | 101 M |
| Receivables | 3.1 M |
| Other Current Assets | 3.58 M |
| Non-Current Assets | 13.2 M |
| Long-Term Investments | 0 |
| PP&E | 10.6 M |
| Other Non-Current Assets | 2.62 M |
| Current Liabilities | 85.8 M |
| Accounts Payable | 1.09 M |
| Short-Term Debt | 5.14 M |
| Other Current Liabilities | 79.5 M |
| Non-Current Liabilities | 35.2 M |
| Long-Term Debt | 4.24 M |
| Other Non-Current Liabilities | 31 M |
EFFICIENCY
Earnings Waterfall
CytomX Therapeutics, Inc.
| Revenue | 138 M |
| Cost Of Revenue | 0 |
| Gross Profit | 138 M |
| Operating Expenses | 113 M |
| Operating Income | 25 M |
| Other Expenses | -6.87 M |
| Net Income | 31.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CytomX Therapeutics, Inc.
| Net Income | 31.9 M |
| Depreciation & Amortization | 146 K |
| Capital Expenditures | -310 K |
| Stock-Based Compensation | 7.67 M |
| Change in Working Capital | -126 M |
| Others | -126 M |
| Free Cash Flow | -86.5 M |
Wall Street Analysts Price Targets
CytomX Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for CTMX of $4.8 , with forecasts ranging from
a
low of
$3.25 to a high of $8 .
CTMX Lowest Price Target
Wall Street Target
3.25 USD
653.19%
CTMX Average Price Target
Wall Street Target
4.8 USD
1011.74%
CTMX Highest Price Target
Wall Street Target
8 USD
1754.00%
4. DIVIDEND
ANALYSIS
CTMX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CytomX Therapeutics, Inc.
Sold
0-3 MONTHS
47.9 K USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
34.9 K USD 5
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
- 1 month ago
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to earnings of $0.01 per share a year ago.
zacks.com
- 1 month ago
CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ET Company Participants Chris Ogden - CFO Sean McCarthy - Chairman and CEO Conference Call Participants Roger Song - Jefferies Joe Catanzaro - Piper Sandler Anupam Rama - JPMorgan Peter Lawson - Barclays Operator Good afternoon, everyone. Thank you for standing by.
seekingalpha.com
- 1 month ago
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 -
globenewswire.com
- 1 month ago
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.
globenewswire.com
- 1 month ago
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?
On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
zacks.com
- 1 month ago
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets.
globenewswire.com
- 1 month ago
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
- 3 months ago
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 -
globenewswire.com
- 3 months ago
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
zacks.com
- 4 months ago
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.
globenewswire.com
- 4 months ago
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 5 months ago
8. Profile
Summary
CytomX Therapeutics, Inc. CTMX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 34.6 M
Dividend Yield
0.00%
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Contact
151 Oyster Point Boulevard, South San Francisco, CA, 94080
https://www.cytomx.com
IPO
Date
Oct. 8, 2015
Employees
119
Officers
Dr. Marcia P. Belvin Ph.D.
Senior Vice President & Chief Scientific Officer
Ms. Danielle Olander-Moghadassian
Senior Vice President & Chief Human Resources Officer
Dr. Yu-Waye Chu M.D.
Chief Medical Officer
Dr. Sean A. McCarthy DPHIL
Chairman & Chief Executive Officer
Mr. Christopher W. Ogden
Chief Financial Officer
Dr. Stephanie Robertson Ph.D.
Senior Vice President of Alliances & Program Leadership
Ms. Dawn Benson
Senior Vice President of Quality & Product Manufacturing
Mr. Lloyd A. Rowland Jr., J.D.
Senior Vice President, General Counsel, Chief Compliance Officer & Secretary
Dr. Hoyoung Huh M.D., Ph.D.
Special Advisor to Chief Executive Officer
Ms. Leslie Robbins
Senior Vice President of Intellectual Property